( en | de | ru )

 

Disambiguation of "Raoult, Didier"

Author of the publication

copydeleteadd this publication to your clipboard
Azithromycin Inhibits the Replication of Zika Virus

, , , , , , and . Journal of Antivirals and Antiretrovirals, 10 (1): 6-11 (2018)
DOI: https://doi.org/10.4172/1948-5964.1000173

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Olivier Raoult

Hélène Raoult

Leo Didier

Didier Béton

Didier Sangiorgio

 

Other publications of authors with the same name

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, , , , , , , and . European Journal of Clinical Microbiology & Infectious Diseases, 39 (6): 1059--1061 (Jun 1, 2020)Tick-borne rickettsioses in America: Unanswered questions and emerging diseases, , and . Current Infectious Disease Reports, 11 (1): 40--50 (January 2009)Spotted fever group rickettsiae in ticks, Morocco., , , , , and . Emerging Infectious Diseases, 14 (7): 1067--1073 (July 2008)Deep Learning Based Bacteria Classification from SEM Images Using a Combination of Membrane and Internal Features., , , , , , , and . CISS, page 13-18. IEEE, (2022)Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century, , and . International Journal of Antimicrobial Agents, 30 (4): 297 - 308 (2007)Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier), , , , , , and . (2020)Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, , , , and . International Journal of Antimicrobial Agents, 55 (4): 105932 (2020)Combination of hydroxychloroquine plus azithromycin as potential treatment for COVID19 patients: pharmacology, safety profile, drug interactions and management of toxicity., , , , , , and . (2020)Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France, , , , , , , , , and 27 other author(s). (2020)Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, , , , , , , , , and 8 other author(s). International Journal of Antimicrobial Agents, 56 (1): 105949 (2020)